Search

The impact of different dental plan types, dental markets, premiums, out-of-pocket costs and enrollee demographics on the enrollee's perceived oral health status is examined. The results show that nonwhites, capitation (CAP) plan enrollees and those with higher out-of-pocket costs are less likely to rate their oral health as 'good', 'very good' or 'excellent' compared with whites fee-for-service (FFS) plan enrollees and those with lower out-of-pocket costs.

The impact of capitated (CAP) and fee-for-service (FFS) dental benefit plans on the enrollees' satisfaction with their plans and their satisfaction with their dentists is examined. It was found that the enrollees generally were satisfied with their plans and their dentists, but those in FFS plans were the most satisfied, with the level of satisfaction increasing proportionately to the amount of premium paid.

This longitudinal study examines perceived unmet dental need in a nationally representative probability sample of HIV-infected persons in medical care. A logistic regression analysis modeled the relationship between unmet need and explanatory variables. We estimate that 40% of HIV/AIDS patients report an unmet need associated with being male, being unemployed, injecting drugs, being heterosexual, lacking dental insurance, and having less education. Disparities in unmet need are related to socioeconomic status rather than to disease stage or ethnicity.

Aims: With recent European Union marketing authorization, tabelecleucel is the first off-the-shelf, allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy approved for the treatment of relapsed/refractory EBV-positive post-transplant lymphoproliferative disease (EBV + PTLD). In the absence of a control arm, real-world evidence can provide a comparative benchmark for single-arm studies in ultra-rare populations. This study assessed the treatment effect of tabelecleucel in the single-arm phase 3 ALLELE study (NCT03394365) versus a treatment group from a multinational, multicenter retrospective chart review study (RS002) of patients with EBV + PTLD., Methods: In ALLELE, patients had disease relapsed/refractory to rituximab ± chemotherapy and received tabelecleucel 2x10 6 cells/kg on days 1, 8, and 15 in 35-day cycles. Patients in RS002 had disease relapsed/refractory to rituximab ± chemotherapy and received next line of systemic therapy between January 2000 and December 2018. Propensity score-based standardized mortality/morbidity ratio weighting was used to achieve balance between treatment and comparator arms. Kaplan-Meier estimators and Cox regression models were used to compare overall survival (OS) in the re-weighted sample., Results: 30 patients ( n  = 14 hematopoietic cell transplant [HCT], n  = 16 solid organ transplant [SOT]) from ALLELE (data cutoff: November 2021) and 84 patients ( n  = 36 HCT, n  = 48 SOT) from RS002 (data lock: January 2021) were included. Median time from diagnosis to first tabelecleucel dose (ALLELE) or start date of next line of systemic therapy (RS002) was 3.6 months. Tabelecleucel was associated with a substantial OS benefit compared with current treatment, with an unadjusted HR of 0.47 (95% confidence interval [CI] 0.25-0.88) and adjusted HR of 0.37 (95% CI 0.20-0.71) when using the start date of the next line of therapy as the index date. Sensitivity analyses yielded consistent results., Conclusions: In this study of real-world data, tabelecleucel was associated with an OS benefit among patients with R/R EBV + PTLD for whom there is high unmet need.